

Ministry of Health

Office of Chief Medical
Officer of Health, Public
Health

Box 12,
Toronto, ON M7A 1N3

Fax: 416 325-8412

Ministère de la Santé

Bureau du médecin
hygiéniste en chef, santé
publique

Boîte à lettres 12
Toronto, ON M7A 1N3

Téléc. : 416 325-8412

September 28, 2026

Dear Health Care Provider,

This letter is to provide details on Ontario's respiratory syncytial virus (RSV) prevention program.

Adult RSV Vaccination

As communicated earlier this year, the publicly funded RSV vaccine is available year-round for older adults per eligibility.

All individuals 75 plus are eligible for the RSV vaccine. Adults aged 60–74 years of age who meet certain high-risk criteria or live in specific higher-risk settings are eligible for the publicly funded RSV vaccine. In alignment with the National Advisory Committee on Immunization (NACI) high-risk criteria, individuals 60-74 years of age requiring home or chronic oxygen therapy have been added to the Ontario high-risk program.

If an individual received a dose of RSV vaccine previously, they do not need to receive another dose this season, as booster doses are not currently recommended.

For additional information on RSV prevention for older adults, please refer to the attached fact sheet. It can also be accessed on the Ontario government website: [Respiratory Syncytial Virus \(RSV\) prevention programs | ontario.ca](#)

RSV Immunization for Infants, High-Risk Children and During Pregnancy

With the significant positive outcomes (i.e. high uptake and reduced hospitalizations) observed through Ontario's RSV prevention program over the past two respiratory illness seasons, Ontario will continue to offer nirsevimab (Beyfortus®) for eligible infants and high-risk children based on demonstrated effectiveness, and duration of protection.

For those interested in an alternative approach, RSVpreF (Abrysvo®) is another safe and effective option to help protect infants against RSV. It may be administered to eligible pregnant women between 28 and 36 weeks gestation to provide protection to infants through the transfer of maternal antibodies before birth. The National Advisory Committee on Immunization (NACI) recommends administration between 28 and 36 weeks gestation based on available safety and efficacy evidence. This recommendation supports broader access and opportunities for immunization. Abrysvo® is authorized by Health Canada for use between 32 and 36 weeks gestation; administration before 32 weeks gestation is considered off-label and is subject to the sole clinical judgment of the health care provider.

Administration of nirsevimab (Beyfortus®) and RSVpreF (Abrysvo®) under the infant RSV prevention program may begin on October 1. The RSV season typically concludes on March 31, and RSV immunizing agents for the infant program should not be administered after this date. If seasonal epidemiology warrants a change, the ministry will provide notice of the revised end date for the infant RSV prevention program.

For additional information on RSV prevention for infants, high-risk children and during pregnancy please refer to the attached fact sheets. They can also be accessed on the Ontario government website: [Respiratory Syncytial Virus \(RSV\) prevention programs | ontario.ca](https://www.ontario.ca/respiratory-syncytial-virus-rsv-prevention-programs)

Access to RSV immunization products will continue to be available through your local public health unit. Details will be provided by your public health unit on accessing products, as well as other local program details.

We thank you for your continued support and dedication to the publicly funded immunization program, protecting those in Ontario against RSV,

Sincerely,



Dr. Kieran Michael Moore, MD, CCFP(EM), FCFP, MPH, DTM&H, FRCPC, FCAHS
Chief Medical Officer of Health and Assistant Deputy Minister, Public Health

Attachments:

1. Older Adult RSV Fact Sheet for Health Care Providers
2. Infant and High-Risk Children RSV Fact Sheet for Health Care Providers